Stock VERU VERU INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Veru Inc.

Equities

VERU

US92536C1036

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-24 pm EDT 		5-day change 1st Jan Change
1.23 USD -3.15% Intraday chart for Veru Inc. -6.82% +70.83%
May. 22 Veru Inc. to Present an Update of Veru's Phase 2B Clinical Program of Enobosarm to Augment Fat Loss and to Avoid Muscle Loss When Combined with GLP-1 Drugs for Weight Loss At the Jefferies Global Healthcare Conference CI
May. 14 B. Riley Securities Starts Very With Buy Rating, $5 Price Target MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Veru to Present at the Jefferies Global Healthcare Conference
AQ
Veru Inc. to Present an Update of Veru's Phase 2B Clinical Program of Enobosarm to Augment Fat Loss and to Avoid Muscle Loss When Combined with GLP-1 Drugs for Weight Loss At the Jefferies Global Healthcare Conference
CI
Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss
AQ
Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week
AQ
B. Riley Securities Starts Very With Buy Rating, $5 Price Target
MT
Veru Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024
CI
Earnings Flash (VERU) VERU Posts Q2 Revenue $4.1M
MT
Transcript : Veru Inc., Q2 2024 Earnings Call, May 08, 2024
Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program
AQ
HC Wainwright Adjusts Veru Price Target to $3 From $2, Maintains Buy Rating
MT
Veru to Present at the GLP-1 Based Therapeutics Summit
AQ
Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024
AQ
Veru : Corporate Presentation, May 2024
PU
Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
AQ
Veru Inc. Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
CI
Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11
AQ
Oppenheimer Cuts Veru Price Target to $5 From $7, Maintains Outperform Rating
MT
Veru Announces Date of 2024 Annual Meeting of Shareholders
AQ
Veru Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023
CI
Raymond James Starts Very With Outperform Rating, $3 Price Target
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VERU Stock
  4. News Veru Inc.